Preclinical positron emission computed tomography of prolonged tumor growth after lutetium-177 prostate-specific membrane antigen treatment in xenograft model of human prostate cancer

• DOI: 10.17816/onco501765
• Publication Date: 2023-12-13T11:21:53Z
• Authors: Olga E. Klementyeva; Alexey A. Lipengolts; Elena Y. Grigorieva; Anna V. Smirnova; Yulia A. Finogenova; Kristina E. Shpakova; Vsevolod A. Skrib...; Yulia S. Lagodzin...
• Keywords: Radionuclide therapy; Glutamate carboxypeptidase II; Lutetium

BACKGROUND: New treatment methods of castration-resistant prostate cancer with radionuclide therapy are needed. They will optimize personalized strategy for metastatic castrate-resistant using low molecular weight ligands to prostate-specific membrane antigen (PSMA) labeled lutetium-177.
 AIM: To define the long-term effects and effectiveness experimental animals PET imaging refine research strategy.
 METHODS: The study was performed in nu/nu male mice PSMA-expressing 22Rv1 xenografts. Positron emission computed tomography 18F-PSMA-1007 used confirm tumor regrowth after a single therapeutic dose [177Lu]Lu-PSMA-IT.
 RESULTS: showed possibility prolonged injection 9.2 MBq [177Lu]Lu-PSMA-IT, which is equivalent minimal human (28.6 MBq/kg).
 CONCLUSIONS: confirmed short period observed effect [177Lu]Lu-PSMA-IT. 2.5 months reduction xenografts non-palpable state by positron 18F-PSMA-1007. These results need frequency repeated administrations radiopharmaceuticals based on PSMA lutetium-177 achieve stable cases where necessary.